Gastric cancer diagnostics market seen reaching $3.87 billion by 2030

The Business Research Company says the global gastric cancer diagnostic market is growing on the back of rising stomach cancer cases, better diagnostic technology and stronger research activity. The market is projected to rise from $2.98 billion in 2026 to $3.87 billion by 2030, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - Gastric cancer diagnostics are central to earlier detection, tumor classification and treatment planning. - The market outlook points to more demand for precise tests as gastric cancer incidence rises worldwide. - Better diagnostics can improve clinical outcomes by identifying malignant lesions sooner.

What happened: - The Business Research Company released its Gastric Cancer Diagnostic Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report estimates the market will grow from $2.78 billion in 2025 to $2.98 billion in 2026. - The report projects the market will reach $3.87 billion by 2030. - The report says the market is growing through advances in technology and greater awareness of early cancer detection. - Download a free sample of the report. - View the full market report.

The details: - The report cites a 7.2% compound annual growth rate for 2025 to 2026. - It projects a 6.8% CAGR through 2030. - Historical growth has been driven by limited availability of fluorescent probes, reliance on traditional single-color FISH methods, expanding genetic research, stronger hospital and laboratory infrastructure, and broader use of basic cytogenetic diagnostic techniques. - Forecast growth is linked to multiplex and high-throughput probes, rising demand for precision medicine, more genetic and pharmaceutical research, better imaging and quantification, and stricter regulatory and quality standards. - Key trends include wider use of multiplex and high-throughput FISH probes, growth in genetic and molecular diagnostics, deeper links with clinical and pharmaceutical research, adoption of advanced imaging and analysis tools, and a stronger focus on probe sensitivity and accuracy. - Gastric cancer diagnostics include tests and procedures used to detect and confirm cancerous tumors in the stomach. - These diagnostics help identify tumors early, classify tumor types and guide treatment decisions. - Rising gastric cancer prevalence is a major growth driver for the global market. - The report links higher gastric cancer risk to unhealthy eating patterns, including high intake of salted, smoked and processed foods. - The American Cancer Society said in May 2024 that new stomach cancer cases in the U.S. rose to 26,890 from 26,500 in 2023. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market story is shifting from basic cytogenetic methods toward more precise molecular and imaging-based diagnostics. - The strongest growth signals are coming from precision medicine, research expansion and tools that improve test sensitivity. - Regional demand suggests mature healthcare systems are driving current revenue, while faster investment and research growth in Asia-Pacific may reshape the market mix.

What's next: - The report expects ongoing adoption of multiplex probes, high-throughput testing and advanced analysis tools. - Market growth will likely track continued investment in genetic research, pharmaceutical research and diagnostic infrastructure. - Regulatory and quality expectations are likely to push further improvements in accuracy and consistency.

The bottom line: - Gastric cancer diagnostics are on a steady growth path, with technology upgrades and rising cancer incidence supporting expansion toward a projected $3.87 billion market by 2030.